JP2019520316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520316A5 JP2019520316A5 JP2018556446A JP2018556446A JP2019520316A5 JP 2019520316 A5 JP2019520316 A5 JP 2019520316A5 JP 2018556446 A JP2018556446 A JP 2018556446A JP 2018556446 A JP2018556446 A JP 2018556446A JP 2019520316 A5 JP2019520316 A5 JP 2019520316A5
- Authority
- JP
- Japan
- Prior art keywords
- bdca2
- seq
- amino acid
- concentration
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 124
- 239000008194 pharmaceutical composition Substances 0.000 claims description 120
- 102100028668 C-type lectin domain family 4 member C Human genes 0.000 claims description 90
- 101000766907 Homo sapiens C-type lectin domain family 4 member C Proteins 0.000 claims description 90
- 239000012634 fragment Substances 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 54
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 48
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 27
- 239000003963 antioxidant agent Substances 0.000 claims description 24
- 230000003078 antioxidant effect Effects 0.000 claims description 24
- 150000003573 thiols Chemical class 0.000 claims description 24
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 23
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 23
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 23
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 23
- 229930006000 Sucrose Natural products 0.000 claims description 23
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 23
- 239000005720 sucrose Substances 0.000 claims description 23
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 22
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 22
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 22
- 229920000053 polysorbate 80 Polymers 0.000 claims description 22
- 229940068968 polysorbate 80 Drugs 0.000 claims description 22
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 20
- 108010053070 Glutathione Disulfide Proteins 0.000 claims description 17
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 claims description 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 16
- 230000037396 body weight Effects 0.000 claims description 15
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 14
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims description 10
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 10
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 9
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 9
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 208000005987 polymyositis Diseases 0.000 claims description 9
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 8
- 235000018417 cysteine Nutrition 0.000 claims description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 8
- 229960003067 cystine Drugs 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 5
- 210000004443 dendritic cell Anatomy 0.000 claims description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 229960003589 arginine hydrochloride Drugs 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022043702A JP2022084782A (ja) | 2016-04-28 | 2022-03-18 | 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン |
| JP2024001801A JP2024038308A (ja) | 2016-04-28 | 2024-01-10 | 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662328959P | 2016-04-28 | 2016-04-28 | |
| US62/328,959 | 2016-04-28 | ||
| PCT/US2017/029802 WO2017189827A1 (en) | 2016-04-28 | 2017-04-27 | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022043702A Division JP2022084782A (ja) | 2016-04-28 | 2022-03-18 | 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019520316A JP2019520316A (ja) | 2019-07-18 |
| JP2019520316A5 true JP2019520316A5 (enExample) | 2020-05-14 |
| JP7045327B2 JP7045327B2 (ja) | 2022-03-31 |
Family
ID=58672794
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018556446A Active JP7045327B2 (ja) | 2016-04-28 | 2017-04-27 | 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン |
| JP2022043702A Pending JP2022084782A (ja) | 2016-04-28 | 2022-03-18 | 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン |
| JP2024001801A Pending JP2024038308A (ja) | 2016-04-28 | 2024-01-10 | 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022043702A Pending JP2022084782A (ja) | 2016-04-28 | 2022-03-18 | 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン |
| JP2024001801A Pending JP2024038308A (ja) | 2016-04-28 | 2024-01-10 | 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190284281A1 (enExample) |
| EP (1) | EP3448425A1 (enExample) |
| JP (3) | JP7045327B2 (enExample) |
| KR (5) | KR20240033168A (enExample) |
| CN (2) | CN116850282A (enExample) |
| AU (2) | AU2017258191B2 (enExample) |
| BR (1) | BR112018072125A2 (enExample) |
| CA (1) | CA3022116A1 (enExample) |
| CO (1) | CO2018012506A2 (enExample) |
| EA (1) | EA201892443A1 (enExample) |
| IL (2) | IL262514B2 (enExample) |
| MA (1) | MA44763A (enExample) |
| MX (3) | MX2018012945A (enExample) |
| NZ (2) | NZ787392A (enExample) |
| PH (1) | PH12018502278A1 (enExample) |
| WO (1) | WO2017189827A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11697670B2 (en) * | 2017-08-22 | 2023-07-11 | Biogen Ma Inc. | Methods for purifying antibodies having reduced high molecular weight aggregates |
| WO2020016417A1 (en) | 2018-07-19 | 2020-01-23 | Ichnos Sciences S.A. | Liquid antibody formulation |
| KR200494676Y1 (ko) | 2020-08-04 | 2021-12-01 | (주) 티나인 | 버튼식 헤어 염색기 |
| CN116963716A (zh) * | 2020-12-03 | 2023-10-27 | 渤健马萨诸塞州股份有限公司 | 治疗皮肤型红斑狼疮和系统性红斑狼疮的方法 |
| KR20230022786A (ko) | 2021-08-09 | 2023-02-16 | 주식회사 인벤테라제약 | 생체 내 주입 후 대식세포에 의해 탐식 및/또는 대사분해되지 않은 상태로 신장을 통해 소변으로 배출되는 나노 구조물 |
| TW202400652A (zh) * | 2022-05-25 | 2024-01-01 | 大陸商映恩生物製藥（蘇州）有限公司 | 抗ｂｄｃａ２抗體及其用途 |
| TW202432188A (zh) * | 2022-12-28 | 2024-08-16 | 大陸商映恩生物製藥（蘇州）有限公司 | 抗ｂｄｃａ２抗體－藥物偶聯物及其用途 |
| WO2025067469A1 (zh) * | 2023-09-28 | 2025-04-03 | 南京维立志博生物科技股份有限公司 | Bdca2单克隆抗体及其和taci组成的融合蛋白及其方法和用途 |
| CN118638234B (zh) * | 2024-07-04 | 2025-10-14 | 杭州博之锐生物制药有限公司 | 抗bdca2抗体及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1610820T4 (da) * | 2003-04-04 | 2013-11-04 | Genentech Inc | Høj-koncentration antistof- og proteinformuleringer |
| ES2780398T3 (es) * | 2012-12-10 | 2020-08-25 | Biogen Ma Inc | Anticuerpo anti-antígeno 2 de células dendríticas sanguíneas y uso de los mismos |
-
2017
- 2017-04-27 MX MX2018012945A patent/MX2018012945A/es unknown
- 2017-04-27 CN CN202310503830.5A patent/CN116850282A/zh active Pending
- 2017-04-27 US US16/095,475 patent/US20190284281A1/en not_active Abandoned
- 2017-04-27 CA CA3022116A patent/CA3022116A1/en active Pending
- 2017-04-27 NZ NZ787392A patent/NZ787392A/en unknown
- 2017-04-27 BR BR112018072125-5A patent/BR112018072125A2/pt active Search and Examination
- 2017-04-27 JP JP2018556446A patent/JP7045327B2/ja active Active
- 2017-04-27 EA EA201892443A patent/EA201892443A1/ru unknown
- 2017-04-27 MA MA044763A patent/MA44763A/fr unknown
- 2017-04-27 CN CN201780032450.0A patent/CN109475623B/zh active Active
- 2017-04-27 AU AU2017258191A patent/AU2017258191B2/en active Active
- 2017-04-27 WO PCT/US2017/029802 patent/WO2017189827A1/en not_active Ceased
- 2017-04-27 KR KR1020247007023A patent/KR20240033168A/ko not_active Ceased
- 2017-04-27 EP EP17722325.2A patent/EP3448425A1/en active Pending
- 2017-04-27 KR KR1020227005469A patent/KR20220028150A/ko not_active Ceased
- 2017-04-27 KR KR1020247035142A patent/KR20240159012A/ko not_active Ceased
- 2017-04-27 KR KR1020187034043A patent/KR102366547B1/ko active Active
- 2017-04-27 KR KR1020257018429A patent/KR20250088784A/ko active Pending
- 2017-04-27 NZ NZ747504A patent/NZ747504A/en unknown
-
2018
- 2018-10-22 IL IL262514A patent/IL262514B2/en unknown
- 2018-10-23 MX MX2025000037A patent/MX2025000037A/es unknown
- 2018-10-23 MX MX2023008075A patent/MX2023008075A/es unknown
- 2018-10-26 PH PH12018502278A patent/PH12018502278A1/en unknown
- 2018-11-22 CO CONC2018/0012506A patent/CO2018012506A2/es unknown
-
2022
- 2022-03-18 JP JP2022043702A patent/JP2022084782A/ja active Pending
-
2024
- 2024-01-10 JP JP2024001801A patent/JP2024038308A/ja active Pending
- 2024-05-15 AU AU2024203240A patent/AU2024203240A1/en active Pending
-
2025
- 2025-02-21 US US19/060,474 patent/US20250289895A1/en active Pending
- 2025-06-17 IL IL321561A patent/IL321561A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019520316A5 (enExample) | ||
| US7785595B2 (en) | Stabilized anti-hepatitis B (HBV) antibody formulations | |
| JP2016535020A5 (enExample) | ||
| JP4879884B2 (ja) | 抗−ｉｌ−９抗体製剤及びその使用法 | |
| JP2018162295A (ja) | 医薬製剤 | |
| RU2021137159A (ru) | Стабильные водные составы на основе антител | |
| JP2017160208A5 (enExample) | ||
| RU2017131618A (ru) | Стабильный жидкий состав для моноклональных антител | |
| JP2019511222A5 (enExample) | ||
| JP2014514346A5 (enExample) | ||
| RU2018107725A (ru) | Стабильный состав на основе антитела к ifnar1 | |
| JP2022036932A5 (enExample) | ||
| IL274846B2 (en) | Formulation for anti-alpha 4 antibody in cell 7 | |
| JP2017537105A5 (enExample) | ||
| JP2008528638A5 (enExample) | ||
| JP2018511609A5 (enExample) | ||
| AR077572A2 (es) | Uso de una composicion que contiene un anticuerpo anti-tnf alfa en la fabricacion de un medicamento y equipo y jeringa cargada conteniendo dicha composicion | |
| JP2018515493A5 (enExample) | ||
| JP2019510739A5 (enExample) | ||
| RU2018100824A (ru) | Антитела, которые связываются с сортилином и подавляют связывание програнулина | |
| JP7398958B2 (ja) | 安定的抗ｏｓｍｒ抗体製剤 | |
| RU2014101207A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| EA031489B1 (ru) | Способ лечения ревматоидного артрита | |
| JP7467438B2 (ja) | 抗ｒｓｖ抗体の製剤及びその使用方法 | |
| JP2018529635A5 (enExample) |